Contact: Catherine Duncan
|Shown at the press conference announcing the $1.99 million investment for CardioVol™ are (left to right) Jim Poage, president and CEO of Startech; Marc Feldman, M.D., founder and CEO of Admittance Technologies; and David Weiss, Ph.D., vice president for research at the UT Health Science Center San Antonio. Dr. Feldman, who developed the new technology, also is a professor of medicine and engineering at the Health Science Center. |
Printer Friendly Format
SAN ANTONIO (Jan. 18, 2013) — Startech announced Jan. 18 the investment of $1.99 million in Admittance Technologies Inc. by the Texas Emerging Technology Fund (ETF).
The investment is for the development and commercialization of Admittance Technologies’ innovative technology platform, CardioVol™, which allows real-time blood volume measurement using existing pacemaker components and lead systems to both detect disease and treat patients with the devices.
Jim Poage, president and CEO of Startech; David Weiss, Ph.D.
, vice president for research at The University of Texas Health Science Center at San Antonio; and Marc Feldman, M.D.
, founder and CEO of Admittance Technologies, participated in the media conference and ceremonial disbursement at the UT Health Science Center San Antonio. Health Science Center research
Dr. Feldman also is a professor of medicine and engineering in the Janey and Dolph Briscoe Division of Cardiology
in the School of Medicine at the UT Health Science Center, as well as the co-winner of the 2010 Chancellor’s Entrepreneurship and Innovation Award
from The University of Texas System.
“We proudly announce Admittance Technologies as the most recent recipient of ETF funding in
San Antonio,” Poage said. “This investment from the ETF is not only an investment in the future of Admittance Technologies but also in the many lives that will benefit from this technology through early detection and prevention of heart failure.”Device offers new hope for cardiac patients
Dr. Feldman said, “We are thankful for the investment from the ETF and the expertise that Startech provided during the process. This funding allows us to move forward with the major proof of concept studies that are necessary to commercialize CardioVol™, our flagship product. CardioVol™ is a technology platform that is ahead of the curve by providing the only device that can determine the hemodynamic stability of ventricular tachycardia, the only available therapy to tune the timing of pacemakers previously implanted in these patients, the earliest detection of impending heart failure, and technology that requires no additional surgery because we are piggybacking into devices already indicated in all patients with weakened hearts.”
“We are always excited to announce new medical technology that was developed in collaboration with our researchers,” said Dr. Weiss. “Investments from the Texas Emerging Technology Fund are vital in allowing our researchers to take their ideas from concept to commercialization.”
John Porterfield, Ph.D., is chief scientific officer of Admittance Technologies. Jonathan Valvano, Ph.D., and John Pearce, Ph.D., are scientific advisors to Admittance Technologies and professors of electrical engineering at UT Austin.###The University of Texas Health Science Center at San Antonio
, one of the country’s leading health sciences universities, ranks in the top 3 percent of all institutions worldwide receiving National Institutes of Health funding. The university’s schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have produced approximately 28,000 graduates. The $736 million operating budget supports eight campuses in San Antonio, Laredo, Harlingen and Edinburg. For more information on the many ways “We make lives better®,” visit www.uthscsa.edu